HUE054990T2 - OGA inhibitor N-[4-fluor-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamid - Google Patents

OGA inhibitor N-[4-fluor-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamid

Info

Publication number
HUE054990T2
HUE054990T2 HUE18703154A HUE18703154A HUE054990T2 HU E054990 T2 HUE054990 T2 HU E054990T2 HU E18703154 A HUE18703154 A HU E18703154A HU E18703154 A HUE18703154 A HU E18703154A HU E054990 T2 HUE054990 T2 HU E054990T2
Authority
HU
Hungary
Prior art keywords
methyl
oxadiazol
thiazol
piperidyl
acetamide
Prior art date
Application number
HUE18703154A
Other languages
English (en)
Inventor
Nicolas Jacques Francois Dreyfus
Peter James Lindsay-Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE054990T2 publication Critical patent/HUE054990T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE18703154A 2017-01-27 2018-01-19 OGA inhibitor N-[4-fluor-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamid HUE054990T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762451137P 2017-01-27 2017-01-27

Publications (1)

Publication Number Publication Date
HUE054990T2 true HUE054990T2 (hu) 2021-10-28

Family

ID=61157343

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18703154A HUE054990T2 (hu) 2017-01-27 2018-01-19 OGA inhibitor N-[4-fluor-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamid

Country Status (36)

Country Link
US (1) US10081625B2 (hu)
EP (1) EP3573983B1 (hu)
JP (1) JP6738970B2 (hu)
KR (1) KR102275338B1 (hu)
CN (1) CN110198940B (hu)
AR (1) AR110747A1 (hu)
AU (1) AU2018213029B2 (hu)
CA (1) CA3049141C (hu)
CL (1) CL2019001978A1 (hu)
CO (1) CO2019007711A2 (hu)
CR (1) CR20190320A (hu)
CY (1) CY1124257T1 (hu)
DK (1) DK3573983T3 (hu)
DO (1) DOP2019000187A (hu)
EA (1) EA038368B1 (hu)
EC (1) ECSP19053616A (hu)
ES (1) ES2871949T3 (hu)
HR (1) HRP20211011T1 (hu)
HU (1) HUE054990T2 (hu)
IL (1) IL267693B (hu)
JO (1) JOP20190182B1 (hu)
LT (1) LT3573983T (hu)
MA (1) MA47368B1 (hu)
MD (1) MD3573983T2 (hu)
MX (1) MX2019008846A (hu)
MY (1) MY197494A (hu)
PE (1) PE20191406A1 (hu)
PH (1) PH12019501707A1 (hu)
PL (1) PL3573983T3 (hu)
PT (1) PT3573983T (hu)
RS (1) RS61979B1 (hu)
SI (1) SI3573983T1 (hu)
TW (1) TWI654978B (hu)
UA (1) UA123472C2 (hu)
WO (1) WO2018140299A1 (hu)
ZA (1) ZA201904171B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
KR20180132060A (ko) 2016-02-25 2018-12-11 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
MX2018010191A (es) 2016-02-25 2019-05-20 Asceneuron S A Inhibidores de glucosidasa.
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
CN112469476B (zh) * 2018-07-31 2024-07-16 伊莱利利公司 5-甲基-4-氟-噻唑-2-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
KR20210060513A (ko) * 2018-09-19 2021-05-26 바이오젠 엠에이 인코포레이티드 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
JP2022510430A (ja) * 2018-12-05 2022-01-26 バイオジェン・エムエイ・インコーポレイテッド モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
WO2020163193A1 (en) * 2019-02-04 2020-08-13 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
CA3160367A1 (en) 2019-12-18 2021-06-24 Jose Manuel Bartolome-Nebreda Oga inhibitor compounds
CA3160405A1 (en) 2019-12-18 2021-06-24 Jose Manuel Bartolome-Nebreda Oga inhibitor compounds
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
AR123031A1 (es) * 2020-07-23 2022-10-26 Lilly Co Eli Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo
BR112023002013A2 (pt) 2020-08-03 2023-05-02 Biogen Ma Inc Formas cristalinas de um inibidor de o-glicoproteína-2-acetamido-2-desóxi-3-d-glucopiranosidase
KR20240099297A (ko) * 2021-10-22 2024-06-28 일라이 릴리 앤드 캄파니 O-GlcNAcase (OGA) 억제제 조합 요법
IL314657A (en) 2022-02-03 2024-09-01 Lilly Co Eli TAU regional imaging for the diagnosis and treatment of Alzheimer's disease
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
CN1777584A (zh) 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
EP2139332A4 (en) * 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
EP2569291B1 (en) 2010-05-11 2016-04-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
WO2014192868A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
JP6563017B2 (ja) * 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
US20180215751A1 (en) 2018-08-02
CR20190320A (es) 2019-08-27
US10081625B2 (en) 2018-09-25
CL2019001978A1 (es) 2019-12-13
EP3573983A1 (en) 2019-12-04
IL267693A (en) 2019-08-29
ZA201904171B (en) 2022-01-26
WO2018140299A1 (en) 2018-08-02
IL267693B (en) 2021-08-31
LT3573983T (lt) 2021-07-26
MA47368B1 (fr) 2021-07-29
TWI654978B (zh) 2019-04-01
MY197494A (en) 2023-06-19
MD3573983T2 (ro) 2021-10-31
KR102275338B1 (ko) 2021-07-12
PL3573983T3 (pl) 2021-10-04
PT3573983T (pt) 2021-06-17
HRP20211011T1 (hr) 2021-09-17
RS61979B1 (sr) 2021-07-30
ECSP19053616A (es) 2019-08-30
JP6738970B2 (ja) 2020-08-12
JP2020504142A (ja) 2020-02-06
ES2871949T3 (es) 2021-11-02
EA201991515A1 (ru) 2020-01-16
EA038368B1 (ru) 2021-08-17
CO2019007711A2 (es) 2019-07-31
DK3573983T3 (da) 2021-06-28
JOP20190182B1 (ar) 2023-03-28
CN110198940B (zh) 2022-09-23
TW201836607A (zh) 2018-10-16
AU2018213029B2 (en) 2020-11-05
EP3573983B1 (en) 2021-04-21
CY1124257T1 (el) 2022-07-22
JOP20190182A1 (ar) 2019-07-25
MX2019008846A (es) 2019-09-10
PE20191406A1 (es) 2019-10-04
NZ754849A (en) 2021-10-29
PH12019501707A1 (en) 2020-03-16
KR20190096421A (ko) 2019-08-19
CA3049141A1 (en) 2018-08-02
CN110198940A (zh) 2019-09-03
DOP2019000187A (es) 2019-08-15
UA123472C2 (uk) 2021-04-07
SI3573983T1 (sl) 2021-08-31
AR110747A1 (es) 2019-05-02
CA3049141C (en) 2021-02-16
BR112019013535A2 (pt) 2020-01-07
AU2018213029A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
IL267693B (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl] Thiazol-2-yl]acetamide as an oga inhibitor
IL245882B (en) Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin
SMT201600057B (it) 3,5-diammino-6-cloro-n-(n-(4-(4-(2-(esil(2,3,4,5,6-pentaidrossiesil)ammino)etossi)fenil)butil)- carbammimidoil)pirazina-2-carbossammide
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
IL252368B (en) 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it
IL230152A (en) METHOD FOR PREPARING n- [5- (aminosulfonyl) -4-methyl-3,1-thiazole-2-ram] n -methyl- 2 - [4 - (2-pyridinyl) phenyl] Acetamide and its monohydrate-saturated salt
BR112015027130A2 (pt) 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
PL3317272T3 (pl) Chwastobójczo skuteczne pochodne N-(1,3,4-oksadiazol-2-ilo)arylokarboksyamidowe
PL3394083T3 (pl) Pochodne n-[5-[(3,4-dimetoksyfenylo)metylo]-1,3,4-tiadiazol-2-ilo]- 2-metoksybenzenoacetamidu i pokrewne związki jako aktywatory cftr do leczenia zaparcia lub cholestazy
ZA201907120B (en) Nitrogen containing heterocycle substituted benzoxazine oxazolidinone compound and preparation method and use thereof
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
ZA202000224B (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
PH12017500123A1 (en) Crystal of azole benzene derivative
PL3212644T3 (pl) Pochodne 2-(1,2,4-triazol-3-ilosulfanylo)-n-1,3,4-tiadiazol-2 -iloacetamidu, które są przydatne w leczeniu cukrzycy
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
EP3402777A4 (en) OXAZOLIDINONE AS TARO INHIBITORS
ZA201603729B (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
UA38200S (uk) Пристрій для ін'єкцій
DK3590853T3 (da) Bearbejdningsanordning til emballagemaskiner
UA40742S (uk) Упаковка для сушок
UA36335S (uk) Упаковка для чорносливу «рrunеs»